Skip to main content
SpringerLink
Log in

Immune tolerance induction for patients with severe hemophilia A: a critical literature review

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

The development of inhibitors that neutralize the function of clotting factor VIII (FVIII) is currently the most challenging complication associated with the treatment of hemophilia A as it increases the disease-related morbidity and mortality. Immune tolerance induction (ITI) is the only documented strategy to eradicate persistent inhibitors in severe hemophilia A patients. Several studies have been conducted so far to identify patient- and treatment-related factors associated with greater ITI success. The currently available literature on ITI in hemophilia A will be critically reviewed in this article. In particular, we will focus on the role of the type of FVIII product on ITI outcome by analyzing the clinical and experimental data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Coppola A, Di Minno MND, Santagostino E (2010) Optimizing management of immune tolerance induction in patients with severe hemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 150:515–528

    Article  PubMed  CAS  Google Scholar 

  2. Tagliaferri A, Rivolta GF, Iorio A, Italian Association of Hemophilia Centers et al (2010) Mortality and causes of death in Italian persons with haemophilia, 1990–2007. Haemophilia 16:437–446

    Article  PubMed  CAS  Google Scholar 

  3. Franchini M, Lippi G (2009) Recent improvement in the clinical treatment of coagulation factor inhibitors. Semin Thromb Hemost 35:806–813

    Article  PubMed  CAS  Google Scholar 

  4. Franchini M, Mannucci PM (2010) Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol (Epub ahead of print)

  5. Lusher JM (2000) Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost 26:179–188

    Article  PubMed  CAS  Google Scholar 

  6. Salomon O, Zivelin A, Livnat T et al (2003) Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 101:4783–4788

    Article  PubMed  CAS  Google Scholar 

  7. Wight J, Paisley S (2003) The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 9:418–435

    Article  PubMed  CAS  Google Scholar 

  8. Key NS (2004) Inhibitors in congenital coagulation disorders. Br J Haematol 127:379–391

    Article  PubMed  CAS  Google Scholar 

  9. Coppola A, Santoro C, Tagliaferri A, Franchini M, Di Minno G (2010) Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies. Haemophilia 16(Suppl 1):13–19

    Article  PubMed  CAS  Google Scholar 

  10. Kempton CL, White CG (2009) How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 113:11–17

    Article  PubMed  CAS  Google Scholar 

  11. Kruse-Jarres R, Barnett B, Leissinger C (2008) Immune tolerance induction for the eradication of inhibitors in patients with hemophilia A. Expert Opin Biol Ther 8:1885–1896

    Article  PubMed  CAS  Google Scholar 

  12. Haya S, Moret A, Cid AR et al (2007) Inhibitors in haemophilia A: current management and open issues. Haemophilia 13(Suppl. 5):52–60

    Article  PubMed  CAS  Google Scholar 

  13. Mariani G, Siragusa S, Kroner BL (2003) Immune tolerance induction in hemophilia A: a review. Semin Thromb Hemost 29:69–76

    Article  PubMed  CAS  Google Scholar 

  14. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E (2007) International workshop on immune tolerance induction: consensus recommendations. Haemophilia 13(Suppl 1):1–22

    Article  PubMed  Google Scholar 

  15. Di Paola J, Aledort L, Britton H et al (2006) Application of current knowledge to the management of bleeding events during immune tolerance induction. Haemophilia 12:591–597

    Article  PubMed  CAS  Google Scholar 

  16. Brackmann HH, Oldenburg J, Schwaab R (1996) Immune tolerance for the treatment of factor VIII inhibitors—twenty years’ ‘Bonn protocol’. Vox Sang 70(Suppl 1):30–35

    Article  PubMed  Google Scholar 

  17. Nilsson IM, Berntorp E, Zettervall O (1988) Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 318:947–950

    Article  PubMed  CAS  Google Scholar 

  18. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM (1995) Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 86:983–988

    PubMed  CAS  Google Scholar 

  19. Ewing NP, Sanders NL, Dietrich SL, Kasper CK (1988) Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 259:65–68

    Article  PubMed  CAS  Google Scholar 

  20. Unuvar A, Warrier I, Lusher JM (2000) Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors. Haemophilia 6:150–157

    Article  PubMed  CAS  Google Scholar 

  21. Rocino A, Papa ML, Salerno E, Capasso F, Miraglia E, De Biasi R (2001) Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution. Haemophilia 7:33–38

    Article  PubMed  CAS  Google Scholar 

  22. Batlle J, Lopez MF, Brackmann HH et al (1999) Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors. Haemophilia 5:431–435

    Article  PubMed  CAS  Google Scholar 

  23. Astermark J, Morado M, Rocino A, on behalf the EHSTB et al (2006) Current European practice in immune tolerance induction therapy in patients with hemophilia and inhibitors. Haemophilia 12:363–371

    Article  PubMed  CAS  Google Scholar 

  24. Mariani G, Ghirardini A, Bellocco R (1994) Immune tolerance in hemophilia—principal results from the international registry. Thromb Haemost 72:155–158

    PubMed  CAS  Google Scholar 

  25. Mariani G, Kroner B (1999) International immune tolerance registry, 1997 update. Vox Sang 77(Suppl 1):25–27

    Article  PubMed  CAS  Google Scholar 

  26. Mariani G, Kroner B (2001) Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica 86:1186–1193

    PubMed  CAS  Google Scholar 

  27. DiMichele DM, Kroner B, North American Immune Tolerance Study Group (2002) The North American immune tolerance registry: practices, outcomes, outcome predictors. Thromb Haemost 87:52–57

    PubMed  CAS  Google Scholar 

  28. DiMichele D (2009) The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia 15:320–328

    Article  PubMed  CAS  Google Scholar 

  29. Lenk H, ITT Study Group (2000) The German registry of immune tolerance treatment in hemophilia—1999 update. Haematologica 85(Suppl 10):45–47

    PubMed  CAS  Google Scholar 

  30. Haya S, Lopez MG, Aznar JA, Battle J (2001) Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish registry. Haemophilia 7:154–159

    Article  PubMed  CAS  Google Scholar 

  31. Coppola A, Margaglione M, Santagostino E, AICE PROFIT Study Group et al (2009) Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 7:1809–1815

    Article  PubMed  CAS  Google Scholar 

  32. DiMichele DM, Hay CR (2006) The international immune tolerance study: a multicenter prospective randomized trial in progress. J Thromb Haemost 4:2271–2273

    Article  PubMed  CAS  Google Scholar 

  33. DiMichele DM, Goldberg I, Foulkes M, Hay CRM, on behalf of the International Immune Tolerance Study Group (2010) International prospective randomized immune tolerance (ITI) study: preliminary results of therapeutic efficacy and safety. Haemophilia 16(Suppl. 4):29 (abstract 07S03)

    Google Scholar 

  34. Gringeri A (2007) VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study. Haemophilia 13(Suppl. 5):73–77

    Article  PubMed  CAS  Google Scholar 

  35. Kroner BL (1999) Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 77(Suppl 1):33–37

    Article  PubMed  Google Scholar 

  36. Kreuz W, Ehrenforth S, Funk M et al (1995) Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1:24–32

    Article  Google Scholar 

  37. Callaghan MU, Rajpurkar M, Chitlur M, Warrier I, Lusher J (2011) Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans? Haemophilia 17:483–489

    Article  PubMed  CAS  Google Scholar 

  38. DiMichele DM (2006) Immune tolerance: critical issues of factor dose, purity and treatment complications. Haemophilia 12(Suppl 6):81–85

    Article  PubMed  Google Scholar 

  39. Berntorp E (2001) Immune tolerance induction: recombinant vs. human-derived product. Haemophilia 7:109–113

    Article  PubMed  CAS  Google Scholar 

  40. Barnes C, Rivard GE, Poon MC et al (2006) Canadian multi-institutional survey of immune tolerance therapy (ITT)—experience with the use of recombinant factor VIII for ITT. Haemophilia 12:1–6

    Article  PubMed  CAS  Google Scholar 

  41. Kreuz W, Ettingshausen CE, Auerswald G et al (2003) Epidemiology of inhibitors and current treatment strategies. Haematologica 88:EREP04

    Google Scholar 

  42. Auerswald G, Spranger T, Brackmann HH (2003) The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 88:EREP05

    PubMed  Google Scholar 

  43. Berntorp E, Nilsson IM (1996) Immune tolerance and the immune modulation protocol. Vox Sang 70(Suppl 1):36–41

    Article  PubMed  Google Scholar 

  44. Orsini F, Rotschild C, Beurrier P, Faradji A, Goudemand J, Polack B (2005) Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 90:1288–1290

    PubMed  CAS  Google Scholar 

  45. Greninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM (2008) The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia 14:295–302

    Article  PubMed  CAS  Google Scholar 

  46. Kurth MA, Dimichele D, Sexauer C et al (2008) Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia 14:50–55

    PubMed  CAS  Google Scholar 

  47. Gringeri A, Musso R, Mazzucconi MG et al (2007) Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 13:373–379

    Article  PubMed  CAS  Google Scholar 

  48. Oldenburg J, Schwaab R, Brackmann HH (1999) Induction of immune tolerance in haemophilia A inhibitor patients by the ‘Bonn Protocol’: predictive parameter for therapy duration and outcome. Vox Sang 77(Suppl 1):49–54

    Article  PubMed  CAS  Google Scholar 

  49. Rocino A, Santagostino E, Mancuso ME, Mannucci PM (2006) Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors. Haematologica 91:558–561

    PubMed  CAS  Google Scholar 

  50. Valentino LA, Recht M, Dipaola J et al (2009) Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A. Haemophilia 15:718–726

    Article  PubMed  CAS  Google Scholar 

  51. Smith MP, Spence KJ, Waters EL et al (1999) Immune tolerance therapy for hemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Thromb Haemost 8:35–38

    Google Scholar 

  52. Platokouki H, Pergantou H, Xafaki P, Komitopoulou A, Aronis S (2009) Immune tolerance induction with high von Willebrand factor/factor VIII content ratio concentrate in children with haemophilia A and high-responding inhibitor. Haemophilia 15:617–619

    Article  PubMed  CAS  Google Scholar 

  53. Rothschild C, Laurian Y, Satre EP et al (1998) French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 80:779–783

    PubMed  CAS  Google Scholar 

  54. Courter SG, Bedrosian CL (2001) Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 38(Suppl 4):52–59

    Article  PubMed  CAS  Google Scholar 

  55. Borel-Derlon A, Lambert T, Rocino A et al (2004) Retrospective assessment of immune tolerance induction with recombinant rAHF, a highly purified, full-length recombinant FVIII, in hemophilia A patients with inhibitors. Haemophilia 10(Suppl 3):53–66

    Google Scholar 

  56. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, the Kogenate Previously Untreated Patient Study Group (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. N Engl J Med 328:453–459

    Article  PubMed  CAS  Google Scholar 

  57. Ter Avest PC, Fischer K, Gouw SC, Van Dijk K, Mauser-Bunschoten EP (2010) Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units. Haemophilia 16:71–79

    Article  PubMed  CAS  Google Scholar 

  58. Unuvar A, Kavakli K, Baytan B et al (2008) Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors. Haemophilia 14:315–322

    Article  PubMed  CAS  Google Scholar 

  59. DiMichele D (2007) Immune tolerance therapy for factor VIII inhibitors: moving from empiricism to an evidence-based approach. J Thromb Haemost 5(Suppl 1):143–150

    Article  PubMed  CAS  Google Scholar 

  60. Franchini M, Lippi G (2010) Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review. Thromb Haemost 104:931–940

    Article  PubMed  CAS  Google Scholar 

  61. Lin Y, Yang X, Chevrier MC et al (2004) Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates. Haemophilia 10:459–469

    Article  PubMed  CAS  Google Scholar 

  62. Astermark J, Voorberg J, Lenk H et al (2003) Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro. Haemophilia 9:567–572

    Article  PubMed  CAS  Google Scholar 

  63. Gensana M, Altisent C, Aznar JA et al (2001) Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 7:369–374

    Article  PubMed  CAS  Google Scholar 

  64. Kallas A, Talpsep T (2001) von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 7:375–380

    Article  PubMed  CAS  Google Scholar 

  65. Berntorp E (1997) Second generation, B-domain deleted recombinant factor VIII. Thromb Haemost 78:256–260

    PubMed  CAS  Google Scholar 

  66. Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K (1996) Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 76:749–754

    PubMed  CAS  Google Scholar 

  67. Reding MT (2006) Immunological aspects of inhibitor development. Haemophilia 12(Suppl 6):30–36

    Article  PubMed  CAS  Google Scholar 

  68. Ghio M, Contini P, Ottonello L et al (2003) Effect of clotting factor concentrates on lymphocyte and neutrophil function in vitro. Thromb Haemost 89:365–373

    PubMed  CAS  Google Scholar 

  69. Thorpe R, Dilger P, Dawson NJ, Barrowcliffe TW (1989) Inhibition of interleukin-2 secretion by factor VIII concentrates: a possible cause of immunosuppression in haemophiliacs. Br J Haematol 71:387–391

    Article  PubMed  CAS  Google Scholar 

  70. Dasgupta S, Repesse Y, Bayry J et al (2007) VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 109:610–612

    Article  PubMed  CAS  Google Scholar 

  71. Santagostino E, Mannucci PM, Bianchi Bonomi A (2000) Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia 6:1–10

    Article  PubMed  CAS  Google Scholar 

  72. United Kingdom Haemophelia Centre Doctors’ Organisation (2003) Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 9:1–23

    Article  Google Scholar 

  73. Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM (2000) The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors’ Organization (UKHCDO). Br J Haematol 111:78–90

    Article  PubMed  CAS  Google Scholar 

  74. Gringeri A, Mannucci PM (2005) Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 11:611–619

    Article  PubMed  CAS  Google Scholar 

  75. Batlle J, Villar A, Liras A et al (2008) Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain. Blood Coagul Fibrinolysis 19:333–340

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no direct or indirect conflicts of interest.

Author information

Authors and Affiliations

  1. Immunohematology and Transfusion Center, “C. Poma” Hospital of Mantova, Mantova, Italy

    Massimo Franchini

  2. Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Parma, Italy

    Giuseppe Lippi

Authors
  1. Massimo Franchini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Lippi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Franchini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Franchini, M., Lippi, G. Immune tolerance induction for patients with severe hemophilia A: a critical literature review. J Thromb Thrombolysis 32, 439–447 (2011). https://doi.org/10.1007/s11239-011-0624-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-011-0624-3

Keywords

Search

Navigation